Scandion Oncology (SCOL) | Spotlight

Home

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-: 0.38
%: 2,50%
Latest: 15.56
High: 15.98
Low: 15.2
Volume: 89 153
Turnover (SEK): 1 372 519
Value (MSEK): 296,5

Board

CEO

Nils Brünner

Chairman Of The Board

Peter Høngaard

Board

Carl Borrebäck
Christian Vinding Thomsen
Jørgen Bardenfleth
Thomas Feldthus

Articles of association

News

2020-03-26 08:38:04 Scandion Oncology CEO Newsletter (March 2020)
2020-03-25 11:41:51 SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells
2020-03-23 15:36:57 Clinical development plans for SCO-101
2020-03-20 14:54:38 Short delay of the antibiotic resistance data
2020-03-10 14:43:31 Chairman, Vice-Chairman and CMO in Scandion Oncology A/S buy Company shares

Show More

News agencies

2020-03-23 16:03:13 Finwire: Usikkerhed omkring antallet af patienter til Scandion Oncology fase II-studie som følge af coronavirus
2020-03-23 15:49:16 Finwire: Scandion Oncology kommenterar pågående studie med SCO-101
2020-03-20 15:14:40 Finwire: Scandion Oncologys djurstudie försenas något av coronaviruset
2020-03-20 15:09:12 Finwire: Coronavirussen forsinker Scandion Oncologys dyrestudie
2020-03-10 15:12:13 Finwire: Scandion Oncology-toppen køber aktier for en halv mio. svenske kroner

Show More

Analysis

2018-10-09 SvD Börsplus: Svår att motstå?

Videos

Key Numbers

*Compiled data from Millistream

Upcoming reports

2020-05-21 Delårsrapport 2020-Q1
2020-05-27 Årsstämma 2019
2020-08-20 Delårsrapport 2020-Q2
2020-11-19 Delårsrapport 2020-Q3

Annual reports, prospectus etc.